-
公开(公告)号:US20070174922A1
公开(公告)日:2007-07-26
申请号:US10373512
申请日:2003-02-24
申请人: Nico Ghilardi , Frederic de Sauvage , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , William Wood
发明人: Nico Ghilardi , Frederic de Sauvage , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , William Wood
IPC分类号: A01K67/027 , C12Q1/68 , G01N33/567 , C07H21/04 , C12P21/06 , C12N5/06 , C07K14/705 , C07K16/28
CPC分类号: C07K14/7158
摘要: The present invention is directed to novel polypeptides having sequence similarity to Interleukin 6 receptor and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
摘要翻译: 本发明涉及与白细胞介素6受体具有序列相似性的新型多肽和编码这些多肽的核酸分子。 本文还提供了包含那些核酸序列的载体和宿主细胞,包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子,与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。
-
2.
公开(公告)号:US20070160576A1
公开(公告)日:2007-07-12
申请号:US11606192
申请日:2006-11-29
申请人: David Arnott , Mercedesz Balazs , Nico Ghilardi , Austin Gurney , Philip Hass , Sarah Hymowitz , James Lee , Wenjun Ouyang , Melissa Starovasnik , Yan Wu
发明人: David Arnott , Mercedesz Balazs , Nico Ghilardi , Austin Gurney , Philip Hass , Sarah Hymowitz , James Lee , Wenjun Ouyang , Melissa Starovasnik , Yan Wu
CPC分类号: C07K16/244 , A61K38/2073 , A61K2039/505 , C07K14/54 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/40 , G01N2500/10 , G01N2800/24 , Y02A50/463
摘要: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
摘要翻译: 本发明涉及一种新型天然存在的人类细胞因子,其由本文称为白细胞介素17A / F(IL-17A / F)的白细胞介素-17和白细胞介素-17F的异源二聚体组成。 本文还提供了包含那些核酸序列的载体和宿主细胞,包含与异源多肽序列融合的本发明多肽的嵌合多肽分子,与本发明的多肽结合的特异性抗体和用于产生 本发明。 本文还提供了治疗退行性软骨疾病和其它炎性疾病的方法。
-
公开(公告)号:US20070136829A1
公开(公告)日:2007-06-14
申请号:US11548639
申请日:2006-10-11
申请人: Nico Ghilardi , Frederic De Sauvage , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , William Wood
发明人: Nico Ghilardi , Frederic De Sauvage , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , William Wood
IPC分类号: A01K67/027 , C12Q1/68 , G01N33/53 , G01N33/567 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号: C07K14/7158
摘要: The present invention is directed to novel polypeptides and variants thereof of GLM-R polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided are methods for detecting agents that modulate the activity of GLM-R. Also provided are methods for diagnosing and for treating disorders characterized by the over or under abundance of monocytes or macrophages.
摘要翻译: 本发明涉及GLM-R多肽的新型多肽及其变体以及编码这些多肽的核酸分子。 本文还提供了包含那些核酸序列的载体和宿主细胞,包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子,与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。 还提供了用于检测调节GLM-R的活性的试剂的方法。 还提供了用于诊断和治疗特征在于单核细胞或巨噬细胞过度或不丰富的疾病的方法。
-
4.
公开(公告)号:US20110256126A1
公开(公告)日:2011-10-20
申请号:US13039201
申请日:2011-03-02
申请人: David P. Arnott , Mercedes Z. Balazs , Nico Ghilardi , Austin L. Gurney , Philip E. Haas , Sarah Hymowitz , James M. Lee , Wenjun Ouyang , Melissa A. Starovasnik , Yan Wu
发明人: David P. Arnott , Mercedes Z. Balazs , Nico Ghilardi , Austin L. Gurney , Philip E. Haas , Sarah Hymowitz , James M. Lee , Wenjun Ouyang , Melissa A. Starovasnik , Yan Wu
IPC分类号: A61K39/395 , A61P7/06 , A61P7/02 , A61P13/12 , A61P25/00 , A61P1/00 , A61P17/00 , A61P17/06 , A61P11/06 , A61P37/06 , A61P19/02 , A61P31/14
CPC分类号: C07K16/244 , A61K38/2073 , A61K2039/505 , C07K14/54 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/40 , G01N2500/10 , G01N2800/24 , Y02A50/463
摘要: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
摘要翻译: 本发明涉及一种新型天然存在的人类细胞因子,其由本文称为白细胞介素17A / F(IL-17A / F)的白细胞介素-17和白细胞介素-17F的异源二聚体组成。 本文还提供了包含那些核酸序列的载体和宿主细胞,包含与异源多肽序列融合的本发明多肽的嵌合多肽分子,与本发明的多肽结合的特异性抗体和用于产生 本发明。 本文还提供了治疗退行性软骨疾病和其它炎性疾病的方法。
-
公开(公告)号:US20090280082A1
公开(公告)日:2009-11-12
申请号:US12395550
申请日:2009-02-27
申请人: Nico GHILARDI , Frederic DeSauvage
发明人: Nico GHILARDI , Frederic DeSauvage
CPC分类号: C07K16/2866 , A61K38/20 , A61K38/208 , A61K2039/505 , C07K2317/74 , G01N2333/715 , G01N2500/04 , G01N2800/24
摘要: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune disorder is at least partially mediated by CD8+ T-cell proliferation.
摘要翻译: 本发明涉及治疗自身免疫性疾病的方法。 在一个实施方案中,本发明涉及治疗自身免疫疾病的方法,包括施用TCCR激动剂。 在一个实施方案中,自身免疫疾病至少部分地由Th1应答介导。 在一个实施方案中,自身免疫疾病至少部分地由CD8 + T细胞增殖介导。
-
公开(公告)号:US20060177436A1
公开(公告)日:2006-08-10
申请号:US11275181
申请日:2005-12-16
申请人: Nico Ghilardi , Frederic DeSauvage
发明人: Nico Ghilardi , Frederic DeSauvage
IPC分类号: A61K39/395
CPC分类号: C07K16/2866 , A61K38/20 , A61K38/208 , A61K2039/505 , C07K2317/74 , G01N2333/715 , G01N2500/04 , G01N2800/24
摘要: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune disorder is at least partially mediated by CD8+ T-cell proliferation.
摘要翻译: 本发明涉及治疗自身免疫性疾病的方法。 在一个实施方案中,本发明涉及治疗自身免疫疾病的方法,包括施用TCCR激动剂。 在一个实施方案中,自身免疫疾病至少部分地由Th1应答介导。 在一个实施方案中,自身免疫疾病至少部分地由CD8 + T细胞增殖介导。
-
-
-
-
-